Benzimidazole derivatives have assumed an imperative moiety in the hypothetical improvement in heterocyclic science and furthermore utilized broadly in organic synthesis. The synthesis, structure and biological activities of benzimidazole derivatives have been focal point of research enthusiasm for the field of medication because of potential exercises displayed by them. Developments of more current lead atoms are utilized to improve pharmacological action and lessen drug toxicities. After extensive literature review it was thought worthwhile to synthesize some Benzimidazole derivatives and evaluate their antibacterial and antifungal activities. A series of new 2-(1H-benzimidazole-2-yl) phenyl)-2-(substituted benzylidene) hydrazine was designed for showing the above activity. The different hydrazine derivatives (4a-4i) were synthesized by using different substituted benzaldehyde compounds. The structures of synthesized compounds were characterized by IR, 1H NMR, Mass spectral data and elemental analysis. Synthesized compounds were tested in vitro for different kinds of pharmacological activity of this class of medications including antibacterial and antifungal action. The compounds 4d and 4e found most active against E.coli and P. aeurigenosa and 4i found to be most active against B.subtilis and S.aureus. The derivative 4c shows good activity against C.albicans and A.niger. Molecular docking analysis was performed to investigate the binding affinity of the synthesized compounds with target proteins. By means of this research it is concluded that Benzimidazole derivatives are a potent compound compressing of different pharmacological activities and this has been proved by docking studies too. Further evaluation of their properties is required before they can be adopted for widespread use.
Published in | Journal of Drug Design and Medicinal Chemistry (Volume 10, Issue 2) |
DOI | 10.11648/j.jddmc.20241002.12 |
Page(s) | 54-66 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Benzimidazole, Antibacterial, Antifungal, Benzaldehyde, Docking Analysis
No of compound | E. coli | B. subtilis | ||||
---|---|---|---|---|---|---|
25ml-1 | 50ml-1 | 100ml-1 | 25ml-1 | 50ml-1 | 100ml-1 | |
4a | 8.22±0.38 | 11.16±0.19 | 15.87±0.16 | 8.42±0.21 | 11.28±0.64 | 15.28±0.17 |
4b | 9.54±0.29 | 14.07±0.41 | 16.67±0.24 | 9.94±0.34 | 10.57±0.17 | 16.65±0.15 |
4c | 7.54±0.23 | 10.97±0.40 | 14.82±0.37 | 8.46±0.19 | 11.69±0.91 | 15.53±0.34 |
4d | 10.24±0.28 | 14.21±0.27 | 15.18±0.43 | 7.43±0.16 | 11.51±0.26 | 14.72±0.27 |
4e | 9.54±0.19 | 11.57±0.64 | 15.02±0.42 | 10.28±0.23 | 14.64±0.46 | 17.22±0.41 |
4f | 9.21± 0.37 | 13.94±0.19 | 15.94±0.84 | 8.87±0.12 | 11.35±0.94 | 15.57±0.47 |
4g | 7.56±0.51 | 10.14±0.72 | 14.54±0.74 | 9.29±0.57 | 11.69±0.16 | 16.32±0.51 |
4h | 8.11±0.14 | 11.56±0.72 | 14.57±0.41 | 10.95±0.78 | 14.39±0.42 | 16.97±0.24 |
4i | 7.79±0.64 | 11.34±0.43 | 15.24±0.87 | 9.42±0.57 | 10.64±0.72 | 15.27±0.43 |
Ciprofloxacin | - | 14.38±0.13 | - | - | 14.82±0.21 | - |
No of compound | P. aeruginosa | S. aureus | ||||
---|---|---|---|---|---|---|
25ml-1 | 50ml-1 | 100ml-1 | 25ml-1 | 50ml-1 | 100ml-1 | |
4a | 10.57±0.35 | 11.36±0.54 | 14.54±0.17 | 10.52±0.11 | 14.08±0.49 | 17.06±0.35 |
4b | 9.54±0.12 | 12.04±0.31 | 15.28±0.35 | 9.14±0.17 | 11.61±0.35 | 14.35±0.29 |
4c | 10.24±0.18 | 14.38±0.46 | 17.5±1 0.17 | 8.87±0.42 | 12.26±0.14 | 15.37±0.64 |
4d | 8.18±0.21 | 11.64±0.54 | 15.21±0.13 | 7.12±0.11 | 10.84±0.49 | 15.87±0.27 |
4e | 10.64±0.17 | 14.24±0.12 | 17.69± 0.37 | 8.57±0.53 | 11.64±0.35 | 15.49±0.17 |
4f | 9.42±0.72 | 11.03±0.31 | 15.68± 0.68 | 7.28±0.33 | 12.54±0.15 | 16.65±0.24 |
4g | 8.27±0.34 | 11.26±0.19 | 14.34± 0.54 | 10.84±0.29 | 13.97±0.46 | 17.28±0.15 |
4h | 8.86±0.47 | 12.35±0.42 | 15.69±0.36 | 7.39±0.74 | 11.31±0.79 | 14.10±0.48 |
4i | 10.86±0.24 | 14.38±0.68 | 16.51±0.74 | 10.27±0.31 | 14.38±0.42 | 15.84±0.28 |
Ciprofloxacin | - | 14.49±0.16 | - | - | 14.79±0.12 | - |
Compounds | C. albicana | A. niger | ||||
---|---|---|---|---|---|---|
25ml-1 | 50ml-1 | 100ml-1 | 25ml-1 | 50ml-1 | 100ml-1 | |
4a | 6.39±0.5 | 8.55±0.3 | 11.6±0.42 | 6.47±0.31 | 8.65±0.59 | 10.9±0.6 |
4b | 7.48±0.2 | 8±0.9 | 10.8± 0.8 | 8.37±0.31 | 9.8±0.5 | 10.42±0.21 |
4c | 8.19±0.17 | 11.47±0.5 | 13.56±0.40 | 8.75±0.37 | 11.15±0.9 | 13.26 ± 0.7 |
4d | 7.60±0.4 | 10.3±0.9 | 12.55±0.5 | 8.04+0.71 | 10.4±0.8 | 12.5±0.31 |
4e | 6.3±0.9 | 9.9±0.2 | 11.3±0.15 | 6.3±0.6 | 9.63±0.7 | 12.70±0.29 |
4f | 7.77±0.3 | 10.9±0.7 | 13.20±0.6 | 8.6±0.3 | 10.6±0.5 | 12.7±0.12 |
4g | 7.89±0.60 | 11.6±0.9 | 13.3±0.41 | 7.52±0.7 | 11.10±0.4 | 13.51±0.4 |
4h | 8.13±0.11 | 11.09±0.97 | 13.02±0.11 | 7.65±0.9 | 11±0.2 | 13.6±0.46 |
4i | 7.9±0.14 | 10.16±0.3 | 12.53±0.46 | 6.63±0.5 | 9.86±0.1 | 12.4±0.8 |
Fluconazole | 12.4±0.5 | 11.2±0.8 |
Code | 3HSB for affinity (kcal/mol) | 1EI1 for affinity (kcal/mol) | 1JIJ for affinity (kcal/mol) | 4ZA4 for affinity (kcal/mol) | 6TZ6 for affinity (kcal/mol) |
---|---|---|---|---|---|
4a | -8.4 | -9.4 | -10.4 | -8.8 | -10.6 |
4b | -9.0 | -9.2 | -8.6 | -8.7 | -10.1 |
4c | -8.5 | -8.9 | -9.2 | -8.4 | -10.1 |
4d | -8.6 | -9.1 | -9.7 | -9.1 | -9.6 |
4e | -8.2 | -9.0 | -9.2 | -8.5 | -9.4 |
4f | -9.0 | -9.9 | -10.0 | -8.8 | -10.6 |
4g | -8.2 | -9.1 | -8.8 | -8.8 | -9.6 |
4h | -8.2 | -9.2 | -9.5 | -8.6 | -9.6 |
4i | -7.6 | -9.6 | -8.1 | -9.0 | -9.8 |
Code | Log P | TPSA | Mol. Wt. | nON | nOHNH | No. of violations |
---|---|---|---|---|---|---|
4a | 6.26 | 98.90 | 357.37 | 7 | 2 | 1 |
4b | 6.98 | 53.07 | 346.82 | 4 | 2 | 1 |
4c | 6.36 | 62.31 | 342.40 | 5 | 2 | 1 |
4d | 6.95 | 53.07 | 346.82 | 4 | 2 | 1 |
4e | 6.33 | 62.31 | 342.40 | 5 | 2 | 1 |
4f | 6.23 | 98.90 | 357.37 | 7 | 2 | 1 |
4g | 6.38 | 62.31 | 342.40 | 5 | 2 | 1 |
4h | 7.00 | 53.07 | 346.82 | 4 | 2 | 1 |
4i | 6.28 | 98.90 | 357.37 | 7 | 2 | 1 |
S. aureus | Staphylococcus aureus |
P. aeureginosa | Pseudomonas aeureginosa |
B. subtilis | Bacillus subtilis |
E. coli | Escherichia coli |
C. albicans | Candida albicans |
A. niger | Aspergillus niger |
Ppm | parts Per Million |
DMSO | Dimethyl Sulfoxide |
[1] | Tahlan S, Kumar S, Ramasamy K, Lim SM, Shah SA, Mani V, Pathania R, Narasimhan B. Design, synthesis and biological profile of heterocyclic benzimidazole analogues as prospective antimicrobial and antiproliferative agents. BMC chemistry2019; 13(1): 50. |
[2] | Vasava MS, Bhoi MN, Rathwa SK, Jethava DJ, Acharya PT, Patel DB, Patel HD. Benzimidazole: A milestone in the field of medicinal chemistry. Mini Rev Med Chem 2020; 20(7): 532-65. |
[3] | Anand K, Wakode S. Synthesis, characterization and biological evaluation of benzimidazole derivatives. IJPSR 2018; 9(2): 617-24. |
[4] | Demirayak Ş, Mohsen UA, Karaburun AÇ. Synthesis and anticancer and anti-HIV testing of some pyrazino [1, 2-a] benzimidazole derivatives. Eur J Med Chem 2002; 37(3): 255-60. |
[5] | Eisa HM, Barghash AE, Badr SM, Farahat AA. Synthesis and antimicrobial activity of certain benzimidazole and fused benzimidazole derivatives. J Med Chem 2010. |
[6] | Galal SA; Hegab KH; Kassab AS; Rodriguez ML; Kerwin SM; Abdel-Mo'men A; El Diwani HI. New transition metal ion complexes with benzimidazole-5-carboxylic acid hydrazides with antitumor activity. Eur J Med Chem 2009; 44(4): 1500-8. |
[7] | Gellis A, Kovacic H, Boufatah N, Vanelle P. Synthesis and cytotoxicity evaluation of some benzimidazole-4, 7-diones as bioreductive anticancer agents. Eur J Med Chem 2008; 43(9): 1858-64. |
[8] | Alp M, Göker H, Brun R, Yıldız S. Synthesis and antiparasitic and antifungal evaluation of 2′-arylsubstituted-1H, 1′ H-[2, 5′] bisbenzimidazolyl-5-carboxamidines. Eur J Med Chem 2009; 44(5): 2002-8. |
[9] | Mann J, Baron A, Opoku-Boahen Y, Johansson E, Parkinson G, Kelland LR, Neidle S. A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity. J Med Chem 2001; 44(2): 138-44. |
[10] | Singh DN, Verma N, Pathak LP, Raghuwanshi S, Shukla PK, Kulshreshtha DK. Synthesis and antifungal activity of novel benzimidazole incorporated anthraquinones. Indian J Heterocycl Chem 2007; 17(2): 161-4. |
[11] | Cee VJ, Downing NS. A one-pot method for the synthesis of 2-aminobenzimidazoles and related heterocycles. Tetrahedron Lett 2006; 47(22): 3747-50. |
[12] | Dubey PK, Babu B, Narayana MV. Synthesis of 2-indolylbenzimidazoles using Fischer’s indole method. Indian J Heterocycl Chem 2007. |
[13] | Sharma D, Kumar N, Pathak D. Synthesis, characterization and biological evaluation of some newer carbazole derivatives. J Serb Chem Soc 2014; 79(2): 125-32. |
[14] | Sharma D, Sharma G. K., Pathak D, Sharma M. C. Synthesis and evaluation of antibacterial, anthelmintic activities of substituted benzimidazoles analogues. Indian Drugs 2017; 54(6): 69-76. |
[15] | Shah H. J., Chaudhari J. A. Synthesis, characterization and biological studies of some novel benzimidazole derivatives. J Chem Pharm Res 2014; 6(7): 1890-1894. |
[16] | Kumar N. and Pathak D., 2019. Synthesis, characterization and biological evaluation of some newer benzimidazole derivatives by mannich reaction. Indian Drugs 56(7). |
APA Style
Bansal, S., Gaur, R., Bhardwaj, H., Kumar, N., Sharma, G. K., et al. (2024). Synthesis, Biological Evaluation and Molecular Docking Studies of Benzimidazole Derivatives Substitutes as New Antimicrobial Agents. Journal of Drug Design and Medicinal Chemistry, 10(2), 54-66. https://doi.org/10.11648/j.jddmc.20241002.12
ACS Style
Bansal, S.; Gaur, R.; Bhardwaj, H.; Kumar, N.; Sharma, G. K., et al. Synthesis, Biological Evaluation and Molecular Docking Studies of Benzimidazole Derivatives Substitutes as New Antimicrobial Agents. J. Drug Des. Med. Chem. 2024, 10(2), 54-66. doi: 10.11648/j.jddmc.20241002.12
AMA Style
Bansal S, Gaur R, Bhardwaj H, Kumar N, Sharma GK, et al. Synthesis, Biological Evaluation and Molecular Docking Studies of Benzimidazole Derivatives Substitutes as New Antimicrobial Agents. J Drug Des Med Chem. 2024;10(2):54-66. doi: 10.11648/j.jddmc.20241002.12
@article{10.11648/j.jddmc.20241002.12, author = {Sonal Bansal and Rishabh Gaur and Harsh Bhardwaj and Nitin Kumar and Gyanendra Kumar Sharma and Shashank Shekher Mishra}, title = {Synthesis, Biological Evaluation and Molecular Docking Studies of Benzimidazole Derivatives Substitutes as New Antimicrobial Agents }, journal = {Journal of Drug Design and Medicinal Chemistry}, volume = {10}, number = {2}, pages = {54-66}, doi = {10.11648/j.jddmc.20241002.12}, url = {https://doi.org/10.11648/j.jddmc.20241002.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jddmc.20241002.12}, abstract = {Benzimidazole derivatives have assumed an imperative moiety in the hypothetical improvement in heterocyclic science and furthermore utilized broadly in organic synthesis. The synthesis, structure and biological activities of benzimidazole derivatives have been focal point of research enthusiasm for the field of medication because of potential exercises displayed by them. Developments of more current lead atoms are utilized to improve pharmacological action and lessen drug toxicities. After extensive literature review it was thought worthwhile to synthesize some Benzimidazole derivatives and evaluate their antibacterial and antifungal activities. A series of new 2-(1H-benzimidazole-2-yl) phenyl)-2-(substituted benzylidene) hydrazine was designed for showing the above activity. The different hydrazine derivatives (4a-4i) were synthesized by using different substituted benzaldehyde compounds. The structures of synthesized compounds were characterized by IR, 1H NMR, Mass spectral data and elemental analysis. Synthesized compounds were tested in vitro for different kinds of pharmacological activity of this class of medications including antibacterial and antifungal action. The compounds 4d and 4e found most active against E.coli and P. aeurigenosa and 4i found to be most active against B.subtilis and S.aureus. The derivative 4c shows good activity against C.albicans and A.niger. Molecular docking analysis was performed to investigate the binding affinity of the synthesized compounds with target proteins. By means of this research it is concluded that Benzimidazole derivatives are a potent compound compressing of different pharmacological activities and this has been proved by docking studies too. Further evaluation of their properties is required before they can be adopted for widespread use. }, year = {2024} }
TY - JOUR T1 - Synthesis, Biological Evaluation and Molecular Docking Studies of Benzimidazole Derivatives Substitutes as New Antimicrobial Agents AU - Sonal Bansal AU - Rishabh Gaur AU - Harsh Bhardwaj AU - Nitin Kumar AU - Gyanendra Kumar Sharma AU - Shashank Shekher Mishra Y1 - 2024/08/20 PY - 2024 N1 - https://doi.org/10.11648/j.jddmc.20241002.12 DO - 10.11648/j.jddmc.20241002.12 T2 - Journal of Drug Design and Medicinal Chemistry JF - Journal of Drug Design and Medicinal Chemistry JO - Journal of Drug Design and Medicinal Chemistry SP - 54 EP - 66 PB - Science Publishing Group SN - 2472-3576 UR - https://doi.org/10.11648/j.jddmc.20241002.12 AB - Benzimidazole derivatives have assumed an imperative moiety in the hypothetical improvement in heterocyclic science and furthermore utilized broadly in organic synthesis. The synthesis, structure and biological activities of benzimidazole derivatives have been focal point of research enthusiasm for the field of medication because of potential exercises displayed by them. Developments of more current lead atoms are utilized to improve pharmacological action and lessen drug toxicities. After extensive literature review it was thought worthwhile to synthesize some Benzimidazole derivatives and evaluate their antibacterial and antifungal activities. A series of new 2-(1H-benzimidazole-2-yl) phenyl)-2-(substituted benzylidene) hydrazine was designed for showing the above activity. The different hydrazine derivatives (4a-4i) were synthesized by using different substituted benzaldehyde compounds. The structures of synthesized compounds were characterized by IR, 1H NMR, Mass spectral data and elemental analysis. Synthesized compounds were tested in vitro for different kinds of pharmacological activity of this class of medications including antibacterial and antifungal action. The compounds 4d and 4e found most active against E.coli and P. aeurigenosa and 4i found to be most active against B.subtilis and S.aureus. The derivative 4c shows good activity against C.albicans and A.niger. Molecular docking analysis was performed to investigate the binding affinity of the synthesized compounds with target proteins. By means of this research it is concluded that Benzimidazole derivatives are a potent compound compressing of different pharmacological activities and this has been proved by docking studies too. Further evaluation of their properties is required before they can be adopted for widespread use. VL - 10 IS - 2 ER -